These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 35045330)
1. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases. Zhou L; Xu G J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330 [TBL] [Abstract][Full Text] [Related]
2. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs. Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J J Vis Exp; 2019 May; (147):. PubMed ID: 31157769 [TBL] [Abstract][Full Text] [Related]
3. USP15 antagonizes CRL4 Nguyen TV Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995 [TBL] [Abstract][Full Text] [Related]
4. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related]
5. Homo-PROTACs for the Chemical Knockdown of Cereblon. Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587 [TBL] [Abstract][Full Text] [Related]
6. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
7. Development of Phenyl-substituted Isoindolinone- and Benzimidazole-type Cereblon Ligands for Targeted Protein Degradation. Nie X; Zhao Y; Tang H; Zhang Z; Liao J; Almodovar-Rivera CM; Sundaresan R; Xie H; Guo L; Wang B; Guan H; Xing Y; Tang W Chembiochem; 2024 Feb; 25(4):e202300685. PubMed ID: 38116854 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Zhu YX; Kortuem KM; Stewart AK Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of thalidomide and its derivatives. Ito T; Handa H Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938 [TBL] [Abstract][Full Text] [Related]
11. [Cereblon as a primary target of IMiDs]. Ito T; Handa H Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822 [TBL] [Abstract][Full Text] [Related]
12. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008 [TBL] [Abstract][Full Text] [Related]
13. Targeting cereblon in hematologic malignancies. Fuchs O Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246 [TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling. Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457 [TBL] [Abstract][Full Text] [Related]
15. [Development of novel cereblon modulators and their target molecules]. Ito T Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190 [TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. Costacurta M; He J; Thompson PE; Shortt J J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536 [TBL] [Abstract][Full Text] [Related]
18. Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon. Wang B; Li M; Cao D; Sun Q; Yu W; Ma J; Ren H; Xu G; Zhou L Cell Mol Life Sci; 2024 Aug; 81(1):349. PubMed ID: 39136771 [TBL] [Abstract][Full Text] [Related]
19. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
20. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]